214 related articles for article (PubMed ID: 37852988)
1. Dopaminergic denervation and associated MRI microstructural changes in the nigrostriatal projection in early Parkinson's disease patients.
López-Aguirre M; Matarazzo M; Blesa J; Monje MHG; Rodríguez-Rojas R; Sánchez-Ferro A; Obeso JA; Pineda-Pardo JA
NPJ Parkinsons Dis; 2023 Oct; 9(1):144. PubMed ID: 37852988
[TBL] [Abstract][Full Text] [Related]
2. Complementary positron emission tomographic studies of the striatal dopaminergic system in Parkinson's disease.
Antonini A; Vontobel P; Psylla M; Günther I; Maguire PR; Missimer J; Leenders KL
Arch Neurol; 1995 Dec; 52(12):1183-90. PubMed ID: 7492293
[TBL] [Abstract][Full Text] [Related]
3. Onset pattern of nigrostriatal denervation in early Parkinson's disease.
Pineda-Pardo JA; Sánchez-Ferro Á; Monje MHG; Pavese N; Obeso JA
Brain; 2022 Apr; 145(3):1018-1028. PubMed ID: 35349639
[TBL] [Abstract][Full Text] [Related]
4. Relationship between neuromelanin and dopamine terminals within the Parkinson's nigrostriatal system.
Martín-Bastida A; Lao-Kaim NP; Roussakis AA; Searle GE; Xing Y; Gunn RN; Schwarz ST; Barker RA; Auer DP; Piccini P
Brain; 2019 Jul; 142(7):2023-2036. PubMed ID: 31056699
[TBL] [Abstract][Full Text] [Related]
5. Hybrid PET-MRI for early detection of dopaminergic dysfunction and microstructural degradation involved in Parkinson's disease.
Shang S; Li D; Tian Y; Li R; Zhao H; Zheng L; Zhang Y; Chen YC; Yin X
Commun Biol; 2021 Oct; 4(1):1162. PubMed ID: 34621005
[TBL] [Abstract][Full Text] [Related]
6. The spatiotemporal changes in dopamine, neuromelanin and iron characterizing Parkinson's disease.
Biondetti E; Santin MD; Valabrègue R; Mangone G; Gaurav R; Pyatigorskaya N; Hutchison M; Yahia-Cherif L; Villain N; Habert MO; Arnulf I; Leu-Semenescu S; Dodet P; Vila M; Corvol JC; Vidailhet M; Lehéricy S
Brain; 2021 Nov; 144(10):3114-3125. PubMed ID: 33978742
[TBL] [Abstract][Full Text] [Related]
7. RGS Proteins as Critical Regulators of Motor Function and Their Implications in Parkinson's Disease.
Ahlers-Dannen KE; Spicer MM; Fisher RA
Mol Pharmacol; 2020 Dec; 98(6):730-738. PubMed ID: 32015009
[TBL] [Abstract][Full Text] [Related]
8. Disease duration and the integrity of the nigrostriatal system in Parkinson's disease.
Kordower JH; Olanow CW; Dodiya HB; Chu Y; Beach TG; Adler CH; Halliday GM; Bartus RT
Brain; 2013 Aug; 136(Pt 8):2419-31. PubMed ID: 23884810
[TBL] [Abstract][Full Text] [Related]
9. Comparative assessment of 6-[
Becker G; Bahri MA; Michel A; Hustadt F; Garraux G; Luxen A; Lemaire C; Plenevaux A
J Neurochem; 2017 May; 141(4):626-635. PubMed ID: 28294334
[TBL] [Abstract][Full Text] [Related]
10. [(18)F]FDOPA and [(18)F]CFT are both sensitive PET markers to detect presynaptic dopaminergic hypofunction in early Parkinson's disease.
Rinne OJ; Nurmi E; Ruottinen HM; Bergman J; Eskola O; Solin O
Synapse; 2001 Jun; 40(3):193-200. PubMed ID: 11304757
[TBL] [Abstract][Full Text] [Related]
11. The relationship between locomotor disability, autonomic dysfunction, and the integrity of the striatal dopaminergic system in patients with multiple system atrophy, pure autonomic failure, and Parkinson's disease, studied with PET.
Brooks DJ; Salmon EP; Mathias CJ; Quinn N; Leenders KL; Bannister R; Marsden CD; Frackowiak RS
Brain; 1990 Oct; 113 ( Pt 5)():1539-52. PubMed ID: 2123119
[TBL] [Abstract][Full Text] [Related]
12. Post mortem studies in Parkinson's disease--is it possible to detect brain areas for specific symptoms?
Jellinger KA
J Neural Transm Suppl; 1999; 56():1-29. PubMed ID: 10370901
[TBL] [Abstract][Full Text] [Related]
13. Serotonin and dopamine transporter PET changes in the premotor phase of LRRK2 parkinsonism: cross-sectional studies.
Wile DJ; Agarwal PA; Schulzer M; Mak E; Dinelle K; Shahinfard E; Vafai N; Hasegawa K; Zhang J; McKenzie J; Neilson N; Strongosky A; Uitti RJ; Guttman M; Zabetian CP; Ding YS; Adam M; Aasly J; Wszolek ZK; Farrer M; Sossi V; Stoessl AJ
Lancet Neurol; 2017 May; 16(5):351-359. PubMed ID: 28336296
[TBL] [Abstract][Full Text] [Related]
14. Microstructural abnormalities of substantia nigra in Parkinson's disease: A neuromelanin sensitive MRI atlas based study.
Safai A; Prasad S; Chougule T; Saini J; Pal PK; Ingalhalikar M
Hum Brain Mapp; 2020 Apr; 41(5):1323-1333. PubMed ID: 31778276
[TBL] [Abstract][Full Text] [Related]
15. A Multi-Scale Computational Model of Levodopa-Induced Toxicity in Parkinson's Disease.
Muddapu VR; Vijayakumar K; Ramakrishnan K; Chakravarthy VS
Front Neurosci; 2022; 16():797127. PubMed ID: 35516806
[TBL] [Abstract][Full Text] [Related]
16. Levodopa induces long-lasting modification in the functional activity of the nigrostriatal pathway.
Riverol M; Ordóñez C; Collantes M; DiCaudo C; Peñuelas I; Arbizu J; Marcilla I; Luquin MR
Neurobiol Dis; 2014 Feb; 62():250-9. PubMed ID: 24076099
[TBL] [Abstract][Full Text] [Related]
17. Dopaminergic correlates of metabolic network activity in Parkinson's disease.
Holtbernd F; Ma Y; Peng S; Schwartz F; Timmermann L; Kracht L; Fink GR; Tang CC; Eidelberg D; Eggers C
Hum Brain Mapp; 2015 Sep; 36(9):3575-85. PubMed ID: 26037537
[TBL] [Abstract][Full Text] [Related]
18. Effect of ghrelin on the motor deficit caused by the ablation of nigrostriatal dopaminergic cells or the inhibition of striatal dopamine receptors.
Suda Y; Kuzumaki N; Narita M; Hamada Y; Shibasaki M; Tanaka K; Tamura H; Kawamura T; Kondo T; Yamanaka A; Narita M
Biochem Biophys Res Commun; 2018 Feb; 496(4):1102-1108. PubMed ID: 29378186
[TBL] [Abstract][Full Text] [Related]
19. Network degeneration in Parkinson's disease: multimodal imaging of nigro-striato-cortical dysfunction.
Ruppert MC; Greuel A; Tahmasian M; Schwartz F; Stürmer S; Maier F; Hammes J; Tittgemeyer M; Timmermann L; van Eimeren T; Drzezga A; Eggers C
Brain; 2020 Mar; 143(3):944-959. PubMed ID: 32057084
[TBL] [Abstract][Full Text] [Related]
20. Striatal 6-[18F]fluorodopa accumulation after combined inhibition of peripheral catechol-O-methyltransferase and monoamine oxidase type B: differing response in relation to presynaptic dopaminergic dysfunction.
Ruottinen HM; Rinne JO; Oikonen VJ; Bergman JR; Haaparanta MT; Solin OH; Ruotsalainen UH; Rinne UK
Synapse; 1997 Dec; 27(4):336-46. PubMed ID: 9372556
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
